Novo Nordisk A/S Stock Hits New 52-Week High (NVO)
NEW YORK (
) --
(NYSE:
) hit a new 52-week high Tuesday as it is currently trading at $133.24, above its previous 52-week high of $132.88 with 29,079 shares traded as of 9:35 a.m. ET. Average volume has been 268,500 shares over the past 30 days.
Novo Nordisk A/S has a market cap of $68.43 billion and is part of the
sector and
industry. Shares are up 12.3% year to date as of the close of trading on Monday.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The company has a P/E ratio of four, below the average drugs industry P/E ratio of 22.5 and below the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Novo Nordisk A/S as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full
Novo Nordisk A/S Ratings Report
.
See all
52-week high stocks
or get investment ideas from our
.
null
